Maximum quantity allowed is 999
Please select the quantity
CAS RN: 82159-09-9 | Product Number: E0906
Epalrestat
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 1G |
€23.00
|
Contact Us | ≥40 |
|
| 5G |
€73.00
|
1 | ≥40 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Specifications
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
Properties (reference)
| Melting Point | 224 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H300 : Fatal if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | XJ5131855 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | II |
| HS Number | 2934999090 |
Application
Aldose Reductase (AR) Inhibitor
References
- Effects of a new aldose reductase inhibitor on various tissues in vitro
- H Terashima, K Hama, R Yamamoto, M Tsuboshima, R Kikkawa, I Hatanaka, Y Shigeta, J. Pharmacol. Exp. Ther. 1984, 229, 226.
- Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients
- An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells
- Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase
- Aldose reductase structures: Implications for mechanism and inhibition
- Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy
- M. A. Ramirez, N. L. Borja, Pharmacotherapy 2008, 28, 646.
PubMed Literature
Articles/Brochures
TCIMAIL
Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number
Incorrect Lot Number is entered
The requested analytical chart is not available. Sorry for the inconvenience.